Cleavage of the Cytoplasmic Domain of the Integrin beta 3 Subunit during Endothelial Cell Apoptosis*

Jere Meredith Jr.Dagger §, Zhaomei Mu, Takaomi Saidoparallel , and Xiaoping Du**

From the  Department of Pharmacology, College of Medicine, University of Illinois, Chicago, Illinois 60612, the Dagger  Department of Vascular Biology, The Scripps Research Institute, La Jolla, California 92037, and the parallel  Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Saitama 351-0198, Japan

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In this study, we report that the cytoplasmic domain of the integrin beta 3 subunit is a target for limited proteolysis during apoptosis of human umbilical vein endothelial cells. Calpain inhibitors inhibited the cleavage of the beta 3 cytoplasmic domain, indicating that calpain is required. Calpain-mediated proteolysis of fodrin was also detected, indicating that calpain is activated during endothelial cell apoptosis. A phosphatase inhibitor, sodium orthovanadate, inhibited endothelial cell apoptosis and cleavage beta 3, suggesting that protein dephosphorylation preceded integrin cleavage in the apoptosis signaling pathway. beta 3 cleavage was observed in cells that were viable, suggesting that it is an early event and not the consequence of post-death proteolysis. The extent of beta 3 cleavage correlated with a loss in the capacity of cells to reattach to matrix proteins. Loss of reattachment capacity during apoptosis was significantly retarded by a calpain inhibitor. As the beta 3 cytoplasmic domain is required for integrin signaling and interaction with the cytoskeleton, our results suggest that cleavage in the beta 3 cytoplasmic domain by calpain or a calpain-like protease negatively regulates integrin-mediated adhesion, signaling, and cytoskeleton association.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Programmed cell death or apoptosis is a cell suicide pathway involved in a variety of physiological and pathological events such as tissue morphogenesis, development, cancer, and neurodegenerative disorders (reviewed in Refs. 1 and 2). The mechanism of programmed cell death involves the activation of various intracellular proteases (reviewed in Ref. 3). The caspase family of proteases appears to play a key role in the signaling pathway (3, 4). In addition to caspases, the Ca2+-dependent neutral protease, calpain, was also found to be activated during apoptosis in T cells and to cleave fodrin during apoptosis (3, 5-8).

Although the role of calpain during apoptosis is not clear, its substrates include several important intracellular signaling and cytoskeletal proteins, particularly those associated with integrin-focal adhesion complexes, such as focal adhesion kinase (pp125fak) (9), pp60src (10, 11), fodrin (12), filamin and talin (13). In addition, we have recently found that calpain cleaves the cytoplasmic domain of the integrin beta 3 subunit, and that calpain cleavage sites flank two NXXY motifs in the beta 3 cytoplasmic domain required for integrin function (14).

Integrins are a family of cell adhesion receptors, each of which is a heterodimer complex of two transmembrane subunits, alpha and beta  (reviewed in Ref. 15). Integrins bind to extracellular matrix adhesion proteins such as vitronectin, fibronectin, collagen, and laminin. Ligand binding to integrins transduces signals across the plasma membrane, resulting in activation of protein kinases, influx of calcium, elevation of intracellular pH, and hydrolysis of membrane phospholipids and reorganization of the cytoskeleton (reviewed in Ref. 16). Integrin-mediated signals are required for the survival of anchorage-dependent cells including endothelial and epithelial cells (17-21). Integrins interact with cytoskeletal proteins at focal adhesion sites and are critical for cytoskeletal organization and morphological characteristics of anchorage-dependent cells (22). Cytoskeleton reorganization and morphological changes such as membrane blebbing occur during apoptosis (3).

To determine if and how integrins are regulated during apoptosis, we investigated the possible relationship between intracellular proteases and integrins. We report here that the cytoplasmic domain of the integrin beta 3 subunit is cleaved during endothelial cell apoptosis and that calpain is likely to be the protease involved. Since the integrin beta -subunit cytoplasmic domain plays an important role in integrin-mediated cell adhesion and signaling (23-34), its proteolysis may block integrin-mediated signals and disrupt cytoskeleton organization during apoptosis.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Rabbit anti-peptide antibody, anti-beta 3C, is directed against the C-terminal 20 amino acid residues of the beta 3 cytoplasmic domain. Rabbit antibody anti-beta 3 was produced using purified beta 3 subunit as an immunogen and is directed against the extracellular domain. These antibodies have been described previously (14). Calpain inhibitors E64 and calpain inhibitor I were purchased from Boehringer Mannheim. The cell-permeable calpain inhibitor E64d was purchased from Sigma, and the antibody specific for calpain-cleaved fodrin was described previously (12).

Cell Culture-- Human umbilical vein endothelial cells (HUVECs)1 were grown and maintained in endothelial cell growth medium (EGM, Clonetics) supplemented with an additional 8% fetal bovine serum (Life Technologies, Inc.). Cells were used between passages 2 and 10.

HUVECs were serum-starved by incubation in serum-free medium containing M199 (Life Technologies, Inc.), 0.1% bovine serum albumin (nuclease- and protease-free; Calbiochem), and insulin, selenium, and transferrin (GMS-G; Life Technologies, Inc.). For incubation in suspension culture, cells were detached with 0.01 M Na2HPO4, 0.15 M NaCl, 2.5 mM EDTA, pH 7.4 (PBS/EDTA) and resuspended in EGM containing 0.5% methylcellulose (Sigma). Cells were plated on tissue culture dishes coated with 2% agarose (Sigma) in M199 medium to prevent attachment (17).

For reattachment experiments, cells incubated in suspension for 12 h were isolated by centrifugation, washed with PBS/EDTA for 5 min at 37 °C and then re-plated on tissue culture dishes in EGM. Cells were allowed to adhere and spread for 30 min. Adherent cells were lysed directly on the dish or were detached by PBS/EDTA and quantitated by cell counts prior to lysis. Unattached cells were collected by centrifugation. Both adherent and unattached cells were solubilized in buffer as described below and analyzed by immunoblotting.

Immunoblotting-- Cells were isolated and washed twice with PBS/EDTA; for serum-starved cells, adherent cells were detached by incubation with PBS/EDTA and then recombined with the floating cells prior to lysis. Cells were lysed by incubation in 1% Triton X-100, 100 mM Tris, pH 7.4, 150 mM NaCl, 10 mM EDTA, 0.1 mM E64, and 1 mM phenylmethylsulfonyl fluoride for 10 min on ice. Lysates were cleared by centrifugation at 14,000 × g for 5 min. Protein concentrations of cell lysates were determined by BCA assay (Pierce). Equivalent amounts of cell lysates were analyzed by SDS-polyacrylamide gel electrophoresis followed by Western blotting either with antibody, anti-beta 3C, against the C-terminal region of the beta 3 cytoplasmic domain or with the anti-beta 3 antibody. Reactions with antibodies were visualized using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech), and Kodak X-Omat AR film. The immunoblots were scanned, and the uncalibrated optical density of each band was quantitated using NIH Image.

Terminal Deoxynucleotidyltransferase-mediated Fluorescein-dUTP Nick End Labeling (TUNEL)-- Cells in suspension were isolated and incubated in PBS/EDTA for 5 min at 37 °C prior to fixation in 2% formaldehyde (methanol-free; Polysciences)/PBS for 15 min at room temperature. Following fixation, cells were washed twice with PBS and then extracted in 0.1% Triton X-100, 0.1% trisodium citrate for 2 min on ice. Cells were washed once with PBS and then incubated in 0.1% bovine serum albumin/PBS for 10 min at room temperature. Cells were labeled by incubation with terminal deoxynucleotidyltransferase and fluorescein-dUTP (Boehringer Mannheim) for 1 h at 37 °C. Labeled cells were washed with PBS and analyzed by flow cytometry (FACScan).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Loss of the Cytoplasmic Domain of the Integrin beta 3 subunit during Suspension-induced Apoptosis-- To investigate the possibility that proteolysis may regulate integrin function during apoptosis, HUVECs were induced to undergo apoptosis by incubation in suspension. We and others have shown previously that endothelial cells undergo apoptosis when cultured in suspension which is characterized by DNA fragmentation and apoptotic morphology (17, 18). In agreement with these previous results, cells in suspension showed characteristic apoptotic morphology (Fig. 1), and DNA fragmentation (Fig. 2). Cells in suspension began to undergo apoptosis after 6 h of incubation, as demonstrated by labeling of fragmented DNA (Fig. 2A). The percentage of apoptotic cells increased with increasing time in suspension (Fig. 2A). Cells incubated in suspension for various lengths of time were solubilized in the presence of protease inhibitors. Equal amounts of lysates were then immunoblotted with anti-beta 3 antibodies. Two different antibodies were used; the antibody anti-beta 3 recognizes epitopes in the extracellular domain, while the antibody anti-beta 3C recognizes epitopes located in the C-terminal 20 residues of the cytoplasmic domain (14). Expression of the extracellular domain epitopes is essentially constant over the time course (anti-beta 3, Fig. 2, B and C). However, expression of the cytoplasmic domain epitopes significantly decreased with increasing lengths of time in suspension (anti-beta 3C, Fig. 2, B and C). These results indicate that the C-terminal domain is lost from a population of beta 3 subunits as a result of suspension culture. The time course of this loss of immunoreactivity with anti-beta 3C paralleled the time course of DNA fragmentation (Fig. 2, compare A and B), suggesting that this effect may be linked to the process of apoptosis.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 1.   Apoptosis of suspension-cultured endothelial cells. Human umbilical vein endothelial cells were cultured either attached (A) or in suspension for 6 h (B) or 24 h (C). Morphology of the cells was examined under a phase contrast microscope.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Suspension culture induces apoptosis and loss of immunoreactivity with the antibody against the C-terminal domain of integrin beta 3 subunit. HUVECs were cultured in suspension for increasing lengths of time. A, cells were labeled by incubation with terminal deoxynucleotidyltransferase (TdT) and fluorescein-dUTP for 1 h at 37 °C. Labeled cell were analyzed by flow cytometry. B, cells were also solubilized and analyzed by Western blot with anti-beta 3 and anti-beta 3C (directed against the C-terminal 20 residues of the integrin cytoplasmic domain). Antibody reactivity was quantitated after scanning with NIH Image software. C, a representative Western blot of the data shown in B. Shown in A and B are the results from three separate experiments (mean ± S.D.).

Cleavage of the Endothelial beta 3 Cytoplasmic Domain by Calpain-- We previously showed that calpain cleaves the cytoplasmic domain of the integrin beta 3 subunit during platelet aggregation (14). Since there have been reports that calpain is activated during apoptosis of T cells (5-7), we investigated whether calpain may be responsible for the loss in endothelial beta 3 cytoplasmic domain immunoreactivity. HUVECs were incubated in suspension for various lengths of time in the absence or presence of the membrane-permeable calpain inhibitor E64d. 20 µM E64d was used since a higher concentration of E64d (100 µM) was toxic to cells. Cell lysates were then analyzed for reactivity with anti-beta 3C by Western blot. As shown in Fig. 3, E64d significantly inhibited the loss of the beta 3 cytoplasmic domain immunoreactivity during apoptosis, indicating that calpain or a calpain-like protease is responsible for the cleavage of the beta 3 cytoplasmic domain. Similar to E64d, another membrane permeable calpain inhibitor, calpain inhibitor I, also inhibited cleavage of the beta 3 cytoplasmic domain (not shown).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   Calpain inhibitor E64d inhibits cleavage of the cytoplasmic domain of the integrin beta 3 subunit. HUVECs were cultured in suspension for increasing lengths of time in the absence (-E64d) or presence of 20 µM E64d (+E64d). Cells were then solubilized and equivalent amounts of lysates were analyzed by Western blots with anti-beta 3C (beta 3C). Optical density was quantitated by scanning and analysis with NIH Image. Relative amounts in loading were estimated by Western blot with anti-beta 3. Relative reactivities are expressed as a percentage of the antibody reaction at the 0 time point (corrected by the loading factor).

Calpain Cleavage of Fodrin during Endothelial Cell Apoptosis-- To verify whether calpain is activated during apoptosis of endothelial cells, we examined whether fodrin, a known calpain substrate (8, 12), is cleaved during suspension culture-induced apoptosis. Lysates from suspension-cultured endothelial cells were immunoblotted with an antibody specifically recognizing a calpain cleavage site (GMMPR) at the N terminus of the 150-kDa calpain-generated fragment of fodrin (12). This antibody recognizes its epitope only when fodrin is cleaved by calpain at this specific site (12). No calpain-generated fragments of fodrin were detected in control endothelial cell lysates. After suspension culture, however, generation of the 150-kDa fodrin fragment was shown by reactivity with the calpain cleavage-specific antibody (Fig. 4). Generation of the 150-kDa fodrin fragment was maximal after 12 h; however, longer incubation in suspension resulted in a decrease in the fodrin fragment reactive with the antibody, suggesting further degradation of fodrin. In the presence of the calpain inhibitor, E64d (20 µM), there was a significant decrease in the generation of the 150-kDa fodrin fragment after 12 h of incubation and the peak of 150-kDa fragment generation was retarded to the 24-h time point. This result indicates that calpain is activated and cleaves fodrin during endothelial cell apoptosis, and, consistent with the effects of E64d on integrin cleavage (Fig. 3), suggests that intracellular calpain-like activity was only partially inhibited by E64d.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 4.   Cleavage of fodrin by calpain during suspension-induced endothelial cell apoptosis. HUVECs were cultured in suspension in the absence (No E64d) or presence of 20 µM E64d (+E64d) for increasing lengths of time, and then solubilized. Equivalent amounts of cell lysates were analyzed by SDS-polyacrylamide gel electrophoresis and immunoblotting with an antibody specifically recognizing a calpain cleavage site (GMMPR) in the N-terminal domain of the calpain-generated 150-kDa fodrin fragment but not intact fodrin.

Cleavage of beta 3 Cytoplasmic Domain Occurs after Initiation of Apoptosis Signaling-- To determine whether the cleavage of beta 3 cytoplasmic domain was a consequence of apoptosis signaling, we tested the effect of a tyrosine phosphatase inhibitor, Na3VO4. We have shown previously that Na3VO4 blocks apoptosis of suspension-cultured HUVECs (17). Cells were incubated in suspension for 12 h in the absence or presence of Na3VO4. In agreement with previous results, Na3VO4 prevented apoptosis of suspension cultured endothelial cells as indicated by TUNEL assay (Fig. 5A). When these suspension-cultured cells were solubilized and immunoblotted with anti-beta 3 antibodies, we found that the beta 3 cytoplasmic domain was protected from cleavage in the presence of Na3VO4 (Fig. 5B). This effect was dose-dependent (data not shown) and correlated with the ability of Na3VO4 to block apoptosis (Fig. 5A). Thus, suspension culture per se is not responsible for the cleavage of beta 3 cytoplasmic domain. Rather, cleavage of beta 3 cytoplasmic domain occurs downstream of protein dephosphorylation in the apoptosis signaling pathway.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of sodium vanadate on the suspension-culture induced loss of the cytoplasmic domain of the integrin beta 3 subunit. HUVECs were cultured either attached (Control), or in suspension for 12 h in the absence (No VO4), or presence of 100 µM sodium vanadate (100 µM VO4). A, cells were analyzed by TUNEL assay to indicate DNA fragmentation during apoptosis. B, cells were solubilized and immunoblotted with anti-beta 3C, directed against the cytoplasmic domain of beta 3 (relative amounts in loading were estimated by Western blot with anti-beta 3). Note that inhibition of the loss of anti-beta 3C epitope in the presence of sodium vanadate correlates with inhibition of DNA fragmentation. This figure shows the results from three separate experiments (mean ± S.D.).

Cleavage of Integrin beta 3 Cytoplasmic Domain during Apoptosis Induced by Serum Withdrawal-- To investigate whether cleavage of the integrin cytoplasmic domain is unique in suspension-culture induced apoptosis, endothelial cells were induced to undergo apoptosis by serum withdrawal. As shown in Fig. 6, cells in serum-free medium became apoptotic, but at a much slower rate compared with that induced by suspension culture. Fig. 6 (D and E) shows a time-dependent reduction in the reaction of anti-beta 3C with the integrin from endothelial cells cultured under serum-free conditions, indicating that cleavage of the integrin cytoplasmic domain occurred during apoptosis induced by serum withdrawal. Thus, cleavage of the integrin beta 3 cytoplasmic domain is not unique for suspension-induced apoptosis, but is likely to be in the convergent signaling pathway induced by different apoptotic stimuli.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 6.   Loss of the cytoplasmic domain of the integrin beta 3 subunit in serum-starved endothelial cells. HUVECs were cultured in serum-containing medium (A) or in serum-free medium for 24 h (B) and 48 h (C). Cells were photographed under a phase contrast microscope (A, B, and C), and equivalent amount of cell lysates were immunoblotted to quantitate reactivity with anti-beta 3C, against the cytoplasmic domain of beta 3 or with anti-beta 3, against the extracellular domain of beta 3. Relative reactivities with anti-beta 3C are shown in D. In a separate experiment, HUVECs were cultured in the control medium (Ctrl) or in serum-free medium (SF) for 72 h, and then solubilized and immunoblotted with anti-beta 3C and anti-beta 3 antibodies (E).

Cleavage of the beta 3 Cytoplasmic Domain Is an Early Event, but Not a Consequence of Cell Death-- We examined whether beta 3 modification occurs as a step in the apoptosis signaling pathway or is a result of post-death proteolysis. To address this issue, we induced endothelial cell apoptosis by incubating cells in suspension culture for 12 h, then separated the late-phase apoptotic cells from cells in earlier phases of the apoptosis pathway. Cells were separated by their ability to re-adhere to serum-coated dishes (vitronectin is known to be the integrin ligand responsible for cell adhesion to serum-coated plates; Ref. 35). We found that nonadherent cells displayed the characteristic apoptotic morphology (not shown, cf. Fig. 1) while reattached cells appeared normal (Fig. 7). Lysates generated from both re-attached cells and nonadherent cells were then analyzed for immunoreactivity with the anti-beta 3C antibody. Equivalent amounts of lysates from adherent endothelial cells were also examined as controls. In comparison with control cells, suspension-cultured cells showed significantly less (about 60%) reactivity with the anti-beta 3C antibody even though these cells reattached to the matrix (Fig. 7). This indicates that cleavage of the beta 3 cytoplasmic domain was initiated before cells lost the capacity to reattach. As dead cells do not adhere, this result suggests that integrin cleavage is not the result of post-death proteolysis. Furthermore, the reattached apoptotic cells appeared to have a normal morphology (Fig. 7, A and B), which also suggests that cleavage of beta 3 is an early event and may be associated with the early phases of apoptosis signaling. Integrin beta 3 from non-adherent cells showed further reduction in immunoreactivity with anti-beta 3C compared with the cells reattached to serum-coated plates (Fig. 7, C and D). Similar results were obtained when cells were replated on collagen or fibronectin (Fig. 7E). Thus, it appears that the majority of integrin beta 3 subunits are cleaved in late phase apoptotic cells that have lost their capacity to reattach and spread onto matrix proteins.


View larger version (60K):
[in this window]
[in a new window]
 
Fig. 7.   Cleavage of the cytoplasmic domain of beta 3 in adherent and non-adherent HUVECs after suspension-culture. HUVECs were cultured either attached (A) or in suspension for 12 h (B) and then allowed to reattach to the tissue culture plates at 37 °C for 30 min. Reattached cells were photographed under a phase contrast microscope (A and B). C, HUVECs were incubated in suspension for 12 h, and then allowed to reattach to serum-coated plates. Reattached cells (Reattached) and cells still in suspension (non-adherent) were separated, solubilized, and immunoblotted with anti-beta 3C and anti-beta 3. Equivalent amounts of control HUVECs (grown attached on culture plates) were simultaneously analyzed for reactivity with antibodies. Results from three experiments (mean ± S.D.) are shown. D, representative Western blots from the experiment described in C. E, suspension cultured HUVECs were allowed to adhere to collagen (Cn)- and fibronectin (Fn)-coated plates. Reattached cells (adherent) and non-adherent cells were separated, solubilized and immunoblotted with anti-beta 3C or anti-beta 3. Equivalent amounts of control HUVECs were simultaneously analyzed for reactivity with antibodies (typical results of two experiments).

Inhibition of the Loss of Cell Re-attachment Capacity by Calpain Inhibitor E64d-- The above study suggests a correlation between the loss of cell reattachment capacity and cleavage of the integrin cytoplasmic domain by calpain. To investigate whether calpain is indeed involved in regulation of cell adhesion during apoptosis, we examined the effects of E64d on cell readhesion. HUVECs were incubated in suspension for increasing lengths of time in the absence or presence of E64d, and then allowed to reattach to tissue culture plates. The percentage of reattached cells at each time point was then determined. Although the percentage of cell reattachment at each time point varied from experiment to experiment, we did observe a significant rescue of cell reattachment in the presence of E64d in each of the these paired experiments at the 6- and 12-h points (Fig. 8). The paired Student's t test of data from three experiments indicated a significant rescue of cell reattachment by E64d (p < 0.01). However, no significant inhibition by E64d was observed after 24 h of incubation in suspension (Fig. 8). Thus, our results suggest that calpain or a calpain-like protease is indeed involved in the loss of cell reattachment capacity during early phases of apoptosis. Incomplete inhibition of reattachment by E64d is consistent with a partial inhibition of calpain or calpain-like proteolytic activity by E64d (cf. Figs. 3 and 4).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 8.   Inhibition of the loss of cell re-attachment in suspension-cultured endothelial cells by calpain inhibitor E64d. HUVECs were cultured in suspension for increasing lengths of time in the absence (-E64d) or presence of 20 µM (tE64d), and then allowed to reattach to tissue culture plates. Reattached cells were quantitated by cell counts, and results expressed as a percentage of total cells. A typical result of three experiments is shown. Paired Student's t test of data from three experiments indicates that the inhibition by E64d at 6- and 12-h points is significant (p < 0.01).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In this study, we have shown that the cytoplasmic domain of integrin beta 3 subunit is cleaved during apoptosis in HUVECs (Fig. 2). Cleavage was detected by loss of reactivity with an anti-peptide antibody, anti-beta 3C, which recognizes the beta 3 C-terminal domain. We showed previously that anti-beta 3C immunoreactivity was lost when the cytoplasmic domain of beta 3 was cleaved by calpain (14). In apoptotic endothelial cells, the loss of anti-beta 3C immunoreactivity was inhibited by two different calpain inhibitors, E64d and calpain inhibitor I (Fig. 3). As these calpain inhibitors do not inhibit caspases (4), caspases are unlikely to be responsible. Also, as these calpain inhibitors do not inhibit DNA fragmentation of suspension-cultured endothelial cells (data not shown), it is unlikely that their effect was due to inhibition of suspension culture-induced apoptosis. Furthermore, cleavage of fodrin by calpain was also detected in the suspension cultured endothelial cells, suggesting that calpain is activated under these conditions (Fig. 4). Thus, the loss of reactivity with anti-beta 3C is likely to result from proteolytic cleavage of beta 3 by calpain. However, since we showed only a partial inhibition of integrin and fodrin cleavage by E64d, we cannot exclude the possibility that a different protease may also be involved.

Cleavage of the integrin beta 3 cytoplasmic domain is linked to the early phase of the convergent apoptosis signaling pathway. This conclusion is supported by several lines of evidence. First, cleavage of beta 3 was induced by two different apoptotic stimuli and was accompanied by induction of the apoptotic phenotypes (DNA fragmentation and morphological changes), suggesting that cleavage may be associated with the convergent apoptotic pathway. Second, cleavage of integrin was blocked by the phosphatase inhibitor sodium orthovanadate, an inhibitor that also blocks endothelial cell apoptosis induced by either suspension culture (Fig. 5) (17) or serum starvation (36), suggesting that the cleavage occurs downstream the activation of protein-tyrosine phosphatase activity in the apoptosis signaling pathway. Although it is not clear how protein phosphatases are involved, it is known that survival of anchorage-dependent cells requires signals initiated by adhesion receptors (e.g. integrins) and growth factor receptors, both of which activate protein-tyrosine kinases as early signaling mechanisms (for reviews, see Refs. 16 and 37). Either abrogation of integrin binding to matrix proteins or growth factor withdrawal may result in changes in the balance between the protein-tyrosine kinase and phosphatase activities, leading to dephosphorylation of intracellular proteins. Thus, the tyrosine phosphatase inhibitor is likely to function in the early phase of apoptosis pathway. Finally, the conclusion that calpain cleavage occurs in the early phase of apoptosis is supported by our finding that cleavage was initiated when cells were still able to readhere and showed apparent normal morphology (Fig. 7).

Cleavage of the integrin beta 3 cytoplasmic domain may negatively regulate integrin functions. Calpain cleavage sites in the beta 3 cytoplasmic domain have been identified in vitro and in platelets; these sites flank the two NXXY motifs (14). The NXXY motif is highly conserved among different integrin beta  subunits, including beta 1 and beta 5 which are also found in endothelial cells. We have evidence that the beta 1 cytoplasmic domain is also a calpain substrate.2 The NXXY motifs in beta 1 and beta 3 are required for the localization of integrins to focal adhesion sites, integrin-mediated tyrosine phosphorylation of signaling molecules such as focal adhesion kinase and also required for regulating ligand binding affinity (26, 28, 38). Truncation of the beta 3 cytoplasmic domain that removes C-terminal sequences containing the NXXY motif abolishes formation of the integrin-focal adhesion complex, abrogates integrin-mediated cell spreading, and inhibits integrin-mediated tyrosine phosphorylation (27, 29, 39, 40). Thus, it is possible that the cleavage of integrin beta  subunits, in concert with the cleavage of other focal adhesion proteins, leads to disruption of integrin-mediated adhesion, signaling, and cytoskeleton organization. In support of this viewpoint, we have observed a correlation between the extent of integrin cleavage and the ability of apoptotic cells to reattach (Fig. 7). In addition, we found that calpain inhibitor E64d significantly retarded the loss of cell reattachment (Fig. 8). Integrin-mediated signaling activates intracellular protein-tyrosine kinase and mitogen-activated protein kinase pathways, which are required for proliferation and survival of anchorage-dependent cells (41-45). Abrogation of integrin signaling induces apoptosis in endothelial cells and other anchorage-dependent cells (17-19, 21). Thus, it is also possible that intracellular disruption of integrin survival signals by calpain cleavage, if occurring to adherent anchorage-dependent cells, serves as a feedback signaling mechanism that induces or accelerates apoptosis.

Interestingly, we found that the suspension cultured cells will re-adhere and spread when ~40% of beta 3 is cleaved, but lose the capacity to re-adhere when ~70% of the integrin is cleaved (Fig. 7). This is very similar to results from studies of patients with Glanzmann's thrombasthenia, a genetic deficiency in the integrin alpha IIbbeta 3. Platelets obtained from heterozygotes (50% alpha IIbbeta 3 expression) showed no significant deficiency in adhesion while platelets expressing less than 30% of functional integrin were abnormal (46). Thus, it appears that cell reattachment may require only a fraction of the total integrins expressed. However, the finding that cells with ~40% of integrin cleaved are still able to reattach does not suggest that the cleavage of a small percentage of integrin will not affect integrin function. Rather, it is possible that cleavage of a small population of integrins, if localized to existing integrin-focal adhesion sites of adherent cells, would abolish integrin signaling and cytoskeleton association in those specific focal adhesion sites, and thus promote cell rounding and detachment. Cleavage of integrin in existing focal adhesion sites of adherent cells is likely since calpain is colocalized in focal adhesion sites (47), and cleaves several focal adhesion proteins (9, 10, 13).

One approach to further determine the roles of calpain cleavage of integrins during apoptosis is to inhibit calpain cleavage of integrin. Experiments using calpain inhibitors, however, are complicated by the fact that calpain cleaves several intracellular proteins and plays multiple roles in cell survival and growth. Calpain inhibitors inhibit the cleavage and clearance of p53, which is pro-apoptotic, and thus induce apoptosis and growth arrest (48, 49). We also have found that high levels of E64d and calpain inhibitor I are toxic. In addition, calpain inhibitors may have nonspecific effects such as inhibition of proteasome activity by calpain inhibitor I (50). Multiple roles of calpain in cells explain previous contradictory results that calpain inhibitors both inhibit and induce apoptosis in different experiments (5-7, 51-54). Thus, further elucidation of the roles of cleavage of integrin in the apoptosis pathway awaits the development of new tools to specifically inhibit integrin cleavage without affecting the other cellular roles of calpain.

    ACKNOWLEDGEMENTS

We thank Dr. Mark H. Ginsberg and Dr. Martin Schwartz for helpful discussions.

    FOOTNOTES

* This work was supported in part by Grant HL52547 from the National Institutes of Health and by a grant from the Campus Research Board of the University of Illinois.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Research Fellow of the American Heart Association California Affiliate.

** Established Investigator of the American Heart Association. To whom correspondence should be addresses: Dept. of Pharmacology (M/C868), University of Illinois, 835 S. Wolcott Ave., Chicago, IL 60612. Tel.: 312-355-0237; Fax: 312-996-1225; E-mail: xdu{at}uic.edu.

1 The abbreviations used are: HUVEC, human umbilical vein endothelial cell; TUNEL, terminal deoxynucleotidyltransferase-mediated fluorescein-dUTP nick end labeling; EGM, endothelial cell growth medium; PBS, phosphate-buffered saline.

2 X. Du, unpublished data.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Steller, H. (1995) Science 267, 1445-1449[Medline] [Order article via Infotrieve]
  2. Thompson, C. B. (1995) Science 267, 1456-1462[Medline] [Order article via Infotrieve]
  3. Martin, S. J., and Green, D. R. (1995) Cell 82, 349-352[Medline] [Order article via Infotrieve]
  4. Nicholson, D. W., A., A., A., T. N., Vaillancourt, J. P., Ding, C. K., Gallant, M., Greau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T.-T., Yu, V. L., and Miller, D. K. (1995) Nature 376, 37-43[CrossRef][Medline] [Order article via Infotrieve]
  5. Squier, M. K., Miller, A. C., Malkinson, A. M., and Cohen, J. J. (1994) J. Cell. Physiol. 159, 229-237[Medline] [Order article via Infotrieve]
  6. Sarin, A., Adams, D. H., and Henkart, P. A. (1993) J. Exp. Med. 178, 1693-1700[Abstract]
  7. Sarin, A., Clerici, M., Blatt, S. P., Hendrix, C. W., Shearer, G. M., and Henkart, P. A. (1994) J. Immunol. 153, 862-872[Abstract/Free Full Text]
  8. Martin, S. J., O'Brien, G. A., Nishioka, W. K., McGahon, A. J., Mahboubi, A., Saido, T. C., and Green, D. R. (1995) J. Biol. Chem. 270, 6425-6428[Abstract/Free Full Text]
  9. Cooray, P., Yuan, Y., Schoenwaelder, S. M., Mitchell, C. A., Salem, H. H., and Jackson, S. P. (1996) Biochem. J. 318, 41-47[Medline] [Order article via Infotrieve]
  10. Oda, A., Druker, B. J., Ariyoshi, H., Smith, M., and Salzman, E. W. (1993) J. Biol. Chem. 268, 12603-12608[Abstract/Free Full Text]
  11. Fox, J. E. (1994) Ann. N. Y. Acad. Sci. 714, 75-87[Abstract]
  12. Saido, T. C., Yokota, M., Nagao, S., Yamaura, I., Tani, E., Tsuchiya, T., Suzuki, K., and Kawashima, S. (1993) J. Biol. Chem. 268, 25239-25243[Abstract/Free Full Text]
  13. Fox, J. E., Goll, D. E., Reynolds, C. C., and Phillips, D. R. (1985) J. Biol. Chem. 260, 1060-1066[Abstract/Free Full Text]
  14. Du, X., Saido, T. C., Tsubuki, S., Indig, F. E., Williams, M. J., and Ginsberg, M. H. (1995) J. Biol. Chem. 270, 26146-26151[Abstract/Free Full Text]
  15. Hynes, R. O. (1992) Cell 69, 11-25[Medline] [Order article via Infotrieve]
  16. Schwartz, M. A., Schaller, M. D., and Ginsberg, M. H. (1995) Annu. Rev. Cell Dev. Biol. 11, 549-599[CrossRef][Medline] [Order article via Infotrieve]
  17. Meredith, J. J., Fazeli, B., and Schwartz, M. A. (1993) Mol. Biol. Cell 4, 953-961[Abstract]
  18. Re, F., Zanetti, A., Sironi, M., Polentarutti, N., Lanfrancone, L., Dejana, E., and Colotta, F. (1994) J. Cell Biol. 127, 537-546[Abstract]
  19. Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., and Cheresh, D. A. (1994) Cell 79, 1157-1164[Medline] [Order article via Infotrieve]
  20. Meredith, J., and Schwartz, M. A. (1997) Trends Cell Biol. 7, 146-150[CrossRef]
  21. Frisch, S. M., and Francis, H. (1994) J. Cell Biol. 124, 619-626[Abstract]
  22. Ruoslahti, E., and Reed, J. C. (1994) Cell 77, 477-478[Medline] [Order article via Infotrieve]
  23. Chen, Y. P., O'Toole, T. E., Ylanne, J., Rosa, J. P., and Ginsberg, M. H. (1994) Blood 84, 1857-1865[Abstract/Free Full Text]
  24. Chen, Y. P., O'Toole, T. E., Shipley, T., Forsyth, J., LaFlamme, S. E., Yamada, K. M., Shattil, S. J., and Ginsberg, M. H. (1994) J. Biol. Chem. 269, 18307-18310[Abstract/Free Full Text]
  25. O'Toole, T. E., Katagiri, Y., Faull, R. J., Peter, K., Tamura, R., Quaranta, V., Loftus, J. C., Shattil, S. J., and Ginsberg, M. H. (1994) J. Cell Biol. 124, 1047-1059[Abstract]
  26. O'Toole, T. E., Ylanne, J., and Culley, B. M. (1995) J. Biol. Chem. 270, 8553-8558[Abstract/Free Full Text]
  27. Ylanne, J., Huuskonen, J., O'Toole, T. E., Ginsberg, M. H., Virtanen, I., and Gahmberg, C. G. (1995) J. Biol. Chem. 270, 9550-9557[Abstract/Free Full Text]
  28. Reszka, A. A., Hayashi, Y., and Horwitz, A. F. (1992) J. Cell Biol. 117, 1321-1330[Abstract]
  29. Ylanne, J., Chen, Y., O'Toole, T. E., Loftus, J. C., Takada, Y., and Ginsberg, M. H. (1993) J. Cell Biol. 122, 223-233[Abstract]
  30. Akiyama, S. K., Yamada, S. S., Yamada, K. M., and LaFlamme, S. E. (1994) J. Biol. Chem. 269, 15961-15964[Abstract/Free Full Text]
  31. Chen, Y. P., Djaffar, I., Pidard, D., Steiner, B., Cieutat, A. M., Caen, J. P., and Rosa, J. P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10169-10173[Abstract]
  32. Hughes, P. E., Diaz-Gonzalez, G. F., Leong, L., Wu, C., McDonald, J. A., Shattil, S. J., and Ginsberg, M. H. (1996) J. Biol. Chem. 271, 6571-6574[Abstract/Free Full Text]
  33. Knezevic, I., Leisner, T. M., and Lam, S. C.-T. (1996) J. Biol. Chem. 271, 16416-16421[Abstract/Free Full Text]
  34. LaFlamme, S. E., Thomas, L. A., Yamada, S. S., and Yamada, K. M. (1994) J. Cell Biol. 126, 1287-1298[Abstract]
  35. Fath, K. R., Edgell, C.-J. S., and Burridge, K. (1989) J. Cell Sci. 92, 67-75[Abstract]
  36. Yang, C., Chang, J., Gorospe, M., and Passaniti, A. (1996) Cell Growth Differ. 7, 161-171[Abstract]
  37. Ullrich, A., and Schlessinger, J. (1990) Cell 61, 203-212[Medline] [Order article via Infotrieve]
  38. Filardo, E. J., Brooks, P. C., Deming, S. L., Damsky, C., and Cheresh, D. A. (1995) J. Cell Biol. 130, 441-450[Abstract]
  39. Leong, L., Hughes, P., Schwartz, M. A., Ginsberg, M. H., and Shattil, S. J. (1995) J. Cell. Sci. 108, 3817-3825[Abstract/Free Full Text]
  40. Tahiliani, P. D., Singh, L., Auer, K. L., and LaFlamme, S. E. (1997) J. Biol. Chem. 272, 7892-7898[Abstract/Free Full Text]
  41. Lipfert, L., Haimovich, B., Schaller, M. D., Cobb, B. S., Parsons, J. T., and Brugge, J. S. (1992) J. Cell Biol. 119, 905-912[Abstract]
  42. Chen, Q., Kinch, M. S., Lin, T. H., Burridge, K., and Juliano, R. L. (1994) J. Biol. Chem. 269, 26602-26605[Abstract/Free Full Text]
  43. Zhu, X., and Assoian, R. K. (1995) Mol. Biol. Cell 6, 273-282[Abstract]
  44. Chen, Q., Lin, T. H., Der, C. J., and Juliano, R. L. (1996) J. Biol. Chem. 271, 18122-18127[Abstract/Free Full Text]
  45. Frisch, S. M., Vuori, K., Ruoslahti, E., and Chan, H. P. (1996) J. Cell Biol. 134, 793-799[Abstract]
  46. George, J. N., Caen, J. P., and Nurden, A. T. (1990) Blood 75, 1383-1395[Medline] [Order article via Infotrieve]
  47. Beckerle, M. C., Burridge, K., DeMartino, G. N., and Croall, D. E. (1987) Cell 51, 569-577[Medline] [Order article via Infotrieve]
  48. Mellgren, R. L., Lu, Q., Zhang, W., Lakkis, M., Shaw, E., and Mericle, M. T. (1996) J. Biol. Chem. 271, 15568-15574[Abstract/Free Full Text]
  49. Kubbutat, M. H., and Vousden, K. H. (1997) Mol. Cell. Biol. 17, 460-468[Abstract]
  50. Shinohara, K., Tomioka, M., Nakano, H., Tone, S., Ito, H., and Kawashima, S. (1996) Biochem. J. 317, 385-388[Medline] [Order article via Infotrieve]
  51. Zhu, W., Murtha, P. E., and Young, C. Y. (1995) Biochem. Biophys. Res. Commun. 214, 1130-1137[CrossRef][Medline] [Order article via Infotrieve]
  52. Gressner, A. M., Lahme, B., and Roth, S. (1997) Biochem. Biophys. Res. Commun. 231, 457-462[CrossRef][Medline] [Order article via Infotrieve]
  53. Lu, Q., and Mellgren, R. L. (1996) Arch. Biochem. Biophys. 334, 175-181[CrossRef][Medline] [Order article via Infotrieve]
  54. Maeda, S., Lin, K. H., Inagaki, H., and Saito, T. (1996) Biochem. Mol. Biol. Int. 39, 447-453[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.